Market Overview

Latin America Conjugate Vaccine Market 2018-2023: A $5.43 Billion Opportunity -


The "Latin
America Conjugate Vaccine Market (2018-2023)"
report has been
added to's offering.

The conjugate vaccine market in Latin America is expected to grow at a
CAGR of 20.4% leading to revenue of USD 5.43 Bn by 2023. By volume, it
is anticipated to reach 839.21 Million units by 2023, expanding at a
CAGR of 20.19%.

Countries in the Americas have been among the first few developing
nations to introduce pneumococcal conjugate vaccines into their Expanded
Programs on Immunization, with 34 countries and territories having
introduced these vaccines as of September 2015.

Market Segmentation

  • Based on disease indication, the market is segmented into
    pneumococcal, haemophilus influenza type B,
    diphtheria-tetanus-pertussis, meningococcal and others.
  • Based on end user, the market is segmented into paediatric and adult.
  • By countries, the Latin American market is divided into Brazil,
    Argentina and the Rest of LATAM.

Key Growth Factors

Latin America has a growing market owing to increase in the incidence of
chronic diseases, government initiatives, and control strategies.


The Latin America Conjugate Vaccine market is expected to grow
positively. There are still a lot of gaps to be filled for a higher
penetration of such vaccines among the masses.

A dearth of data on HIB disease burden and limited awareness of HIB
disease has resulted in a lack of advocacy for the introduction of HIB
vaccine in some countries.

Highly complicated manufacturing processes, pricing inefficiencies and
lack of accessibility are some of the major obstacles in the growth
path, which need to be addressed.

Key Players Featured

  • Pfizer Inc.
  • Merck & Co.
  • Novartis
  • Sanofi Pasteur
  • CSL Limited

Key Topics Covered

Chapter 1. Executive Summary

Chapter 2. Market Overview

Chapter 3. Latin America Major Segment Overview - by Disease Indication

Chapter 4. Latin America Major Segment Overview - by End User

Chapter 5. Brazil - by Disease Indication

Chapter 6. Brazil - by End User

Chapter 7. Argentina - by Disease Indication

Chapter 8. Argentina - by End User

Chapter 9. Rest of LATAM - by Disease Indication

Chapter 10. Rest of LATAM - by End User

Chapter 11. Competitive Landscape

For more information about this report visit

View Comments and Join the Discussion!